Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy of systemic sclerosis (scleroderma)

U Müller-Ladner1, K Benning, B Lang

  • 1Medizinische Klinik und Poliklinik I, Universität Regensburg.

The Clinical Investigator
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Workplace bullying and suicidal ideation and behaviour: a systematic review and meta-analysis.

Public health·2023
Same author

A feline model of spontaneously occurring autoimmune limbic encephalitis.

Veterinary journal (London, England : 1997)·2023
Same author

Factors influencing nodal yield in neck dissections for head and neck malignancies.

The Journal of laryngology and otology·2023
Same author

Dysphagia incidence in intensive care unit patients with coronavirus disease 2019: retrospective analysis following systematic dysphagia screening.

The Journal of laryngology and otology·2022
Same author

Safety of elective paediatric surgery during the coronavirus disease 2019 pandemic.

International journal of pediatric otorhinolaryngology·2021
Same author

Outcomes of preoperative real-time polymerase chain reaction testing for SARS CoV-2 in elective otolaryngology surgical patients during the pandemic: a prospective cohort study.

The British journal of surgery·2021
Same journal

Are heart rate responses reproducible in the tilt-table test?

The Clinical investigator·1994
Same journal

Cyclosporine A enhances total cell calcium independent of Na-K-ATPase in vascular smooth muscle cells.

The Clinical investigator·1994
Same journal

Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure.

The Clinical investigator·1994
Same journal

Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

The Clinical investigator·1994
Same journal

Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.

The Clinical investigator·1994
Same journal

Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts.

The Clinical investigator·1994
See all related articles

Systemic sclerosis (scleroderma) treatment remains challenging, with limited success from traditional therapies. Recent advancements offer new hope for managing symptoms and organ involvement in scleroderma patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Systemic sclerosis (scleroderma) poses significant challenges in patient and physician management.
  • Established treatments like physiotherapy and D-penicillamine often yield unsatisfactory results.
  • Recent therapeutic progress has been made in specific complications of scleroderma.

Purpose of the Study:

  • To review current disease-modifying therapies for systemic sclerosis (scleroderma).
  • To discuss recent advances in managing specific scleroderma manifestations.
  • To cover therapeutic strategies targeting fibroblasts, vascular alterations, and immune systems.

Main Methods:

  • Literature review of established and emerging systemic sclerosis (scleroderma) treatments.

Related Experiment Videos

  • Analysis of therapies targeting collagen-producing fibroblasts.
  • Examination of treatments for vascular complications and immune system modulation.

    • Main Results:

    • Traditional systemic sclerosis (scleroderma) treatments show limited efficacy.
    • New treatments show promise for Raynaud's phenomenon, scleroderma renal crisis, and gastric hypomotility.
    • Therapeutic approaches now address underlying disease mechanisms like fibroblast activity and immune response.

    Conclusions:

    • Systemic sclerosis (scleroderma) management requires a multi-faceted approach.
    • Advances in treating specific complications improve patient outcomes.
    • Targeting disease mechanisms offers potential for more effective disease-modifying therapy.